Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Patent Bill May Get Stuck In “Second Window” Review; Amgen Urges Pilot

Executive Summary

The fate of proposed legislative reforms to the patent system may rest on discussions between the pharma and tech industries

You may also be interested in...



Amended Patent Bill Limits Opportunities For “Second Window” Review

A new version of patent reform legislation would allow a patent to be challenged anytime during its life, but set stricter requirements for requesting a review after the first year

Amended Patent Bill Limits Opportunities For “Second Window” Review

A new version of patent reform legislation would allow a patent to be challenged anytime during its life, but set stricter requirements for requesting a review after the first year

Patent Reform Bill Gets Cool Reception From Rx Industry; Damage Cap Is Worry

A new patent reform bill introduced in Congress is likely to undergo revisions in the face of criticism from the pharmaceutical industry

Related Content

UsernamePublicRestriction

Register

PS048308

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel